Ken Griffin Catalyst Pharmaceuticals, Inc. Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 21,200 shares of CPRX stock, worth $520,248. This represents 0.0% of its overall portfolio holdings.

Number of Shares

21,200

Previous 13,400 58.21%

Holding current value

$520,248

Previous $279,000 84.23%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$19.53 - $25.74 $4.86 Million - $6.41 Million	248,949 Added 57.04%	685,416 $16.6 Million
Q4 2024 Feb 14, 2025	BUY	$19.73 - $23.93 $8.11 Million - $9.84 Million	411,229 Added 1629.4%	436,467 $9.11 Million
Q3 2024 Nov 14, 2024	SELL	$15.19 - $21.35 $8.47 Million - $11.9 Million	-557,683 Reduced 95.67%	25,238 $501,000
Q2 2024 Aug 14, 2024	SELL	$14.68 - $16.92 $7.86 Million - $9.06 Million	-535,519 Reduced 47.88%	582,921 $9.03 Million
Q1 2024 May 15, 2024	BUY	$13.18 - $17.11 $8.02 Million - $10.4 Million	608,336 Added 119.26%	1,118,440 $17.8 Million
Q4 2023 Feb 14, 2024	BUY	$11.78 - $17.29 $344,930 - $506,268	29,281 Added 6.09%	510,104 $8.57 Million
Q3 2023 Nov 14, 2023	BUY	$11.69 - $15.02 $3.69 Million - $4.74 Million	315,729 Added 191.24%	480,823 $5.62 Million
Q2 2023 Aug 14, 2023	SELL	$11.5 - $18.08 $3.04 Million - $4.78 Million	-264,519 Reduced 61.57%	165,094 $2.22 Million
Q1 2023 May 15, 2023	BUY	$14.34 - $21.05 $5.5 Million - $8.08 Million	383,866 Added 839.11%	429,613 $7.12 Million
Q4 2022 Feb 14, 2023	BUY	$12.25 - $19.5 $560,400 - $892,066	45,747 New	45,747 $850,000
Q2 2022 Aug 15, 2022	SELL	$6.23 - $8.57 $121,254 - $166,797	-19,463 Reduced 9.12%	193,949 $1.36 Million
Q1 2022 May 16, 2022	BUY	$5.31 - $8.31 $133,965 - $209,652	25,229 Added 13.41%	213,412 $1.77 Million
Q4 2021 Feb 14, 2022	SELL	$5.21 - $7.45 $377,078 - $539,201	-72,376 Reduced 27.78%	188,183 $1.27 Million
Q3 2021 Nov 15, 2021	BUY	$4.85 - $6.04 $259,552 - $323,236	53,516 Added 25.85%	260,559 $1.38 Million
Q2 2021 Aug 16, 2021	BUY	$4.29 - $6.05 $701,440 - $989,211	163,506 Added 375.56%	207,043 $1.19 Million
Q1 2021 May 17, 2021	SELL	$3.45 - $4.69 $479,550 - $651,910	-139,000 Reduced 76.15%	43,537 $201,000
Q4 2020 Feb 16, 2021	SELL	$2.97 - $3.83 $82,126 - $105,907	-27,652 Reduced 13.16%	182,537 $610,000
Q3 2020 Nov 16, 2020	SELL	$2.97 - $5.08 $1.97 Million - $3.38 Million	-664,523 Reduced 75.97%	210,189 $625,000
Q1 2020 May 15, 2020	SELL	$2.61 - $5.21 $828,541 - $1.65 Million	-317,449 Reduced 26.63%	874,712 $3.37 Million
Q4 2019 Feb 14, 2020	BUY	$3.67 - $5.7 $4.14 Million - $6.44 Million	1,129,323 Added 1797.2%	1,192,161 $4.47 Million
Q3 2019 Nov 14, 2019	SELL	$3.89 - $7.43 $160,812 - $307,156	-41,340 Reduced 39.68%	62,838 $333,000
Q2 2019 Aug 14, 2019	BUY	$2.7 - $6.11 $239,919 - $542,928	88,859 Added 580.06%	104,178 $400,000
Q1 2019 May 15, 2019	SELL	$2.11 - $5.33 $117,896 - $297,813	-55,875 Reduced 78.48%	15,319 $0
Q4 2018 Feb 14, 2019	BUY	$1.92 - $3.62 $103,537 - $195,212	53,926 Added 312.29%	71,194 $136,000
Q3 2018 Nov 13, 2018	BUY	$2.81 - $3.78 $9,039 - $12,160	3,217 Added 22.9%	17,268 $0
Q2 2018 Aug 10, 2018	SELL	$2.26 - $3.84 $197,528 - $335,623	-87,402 Reduced 86.15%	14,051 $0
Q1 2018 May 11, 2018	SELL	$2.39 - $4.01 $125,190 - $210,047	-52,381 Reduced 34.05%	101,453 $242,000
Q4 2017 Feb 09, 2018	BUY	$2.51 - $4.4 $360,679 - $632,266	143,697 Added 1417.55%	153,834 $602,000
Q3 2017 Nov 09, 2017	BUY	$2.4 - $2.94 $24,328 - $29,802	10,137	10,137 $26,000

Others Institutions Holding CPRX

# of Institutions

388

Shares Held

99.3M

Call Options Held

37K

Put Options Held

20.5K

View Full List

About CATALYST PHARMACEUTICALS, INC.

Ticker CPRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 102,820,000
Market Cap $2.52B
Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...

More about CPRX

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account